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Aim To evaluate the clinical value of serum high mobility 
group box chromosomal protein 1 (HMGB1) levels in making 
the early diagnosis of recurrent cervical squamous cell carci-
nomas (CSCC) and compare it with the value of serum squa-
mous cell carcinoma antigen (SCCA), cytokeratin fragment 
(CYFRA) 21-1, and carcinoembryonic antigen (CEA) levels.
Methods Immunohistochemical staining of tissue from 64 
patients with recurrent CSCCs, 72 patients with non-recurrent 
carcinoma, and 28 healthy participants was performed to de-
termine the expression of HMGB1 protein. The serum levels 
of the 4 markers in 112 patients with recurrent CSCC, 174 pa-
tients with non-recurrent disease, and 128 healthy participants 
were measured by enzyme-linked immunosorbent assay. The 
receiver operating characteristic (ROC) curves were construct-
ed and the area under the curve (AUC) was calculated.
Results Higher immunostaining score was found in recur-
rent CSCC tissue sections than in non-recurrent CSCC sec-
tions. Serum HMGB1 levels in patients with recurrent CSCC 
were significantly higher than in patients with non-recurrent 
disease and healthy controls. The AUC of HMGB1, SCCA, CY-
FRA21-1, and CEA was 0.816, 0.768, 0.703, and 0.625, respec-
tively. HMGB1 had the best specificity and positive likelihood 
ratio (78.0% and 3.25, respectively), whereas SCCA had the 
best sensitivity and negative likelihood ratio (76.3% and 0.34, 
respectively). Parallel combined measurements increased the 
diagnostic sensitivity and serial combination increased the 
specificity. High serum HMGB1 levels were inversely correlat-
ed with disease-free survival (P = 0.009, Pearson χ2 test) and 
overall survival (P = 0.018).
Conclusion HMGB1 was overexpressed in recurrent CSCCs. 
Serum HMGB1 level could be a useful and specific marker for 
evaluating the disease recurrence and predicting prognosis 
in patients with CSCC. Serial combined measurements of se-
rum HMGB1, SCCA, and CYFRA21-1 increased the diagnostic 
specificity, and parallel combined testing increased the diag-
nostic sensitivity.
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Cervical carcinoma, one of the most frequent malignant 
tumors of the female reproductive system, remains to be 
among the leading causes of cancer-related death among 
women globally (1,2). Approximately 30% of Internation-
al Federation of Gynecology and Obstetrics (FIGO) stage 
IB2 to stage IV cases will ultimately recur, despite mod-
ern multimodality treatment (3,4). Mostly, recurrence and 
metastasis occur in the local cervix, pelvic wall, and retro-
peritoneal lymph node. It is difficult to distinguish those 
diseases, except local relapse from radiation reaction or or-
ganized lymphocyst. One of the methods to identify early 
recurrence and prolong overall survival is screening of as-
ymptomatic patients (5). In clinical practice, some tumor 
markers which can improve the sensitivity and specificity 
of diagnosis and prognostic prediction of recurrent cervi-
cal cancer have been used (6-9). Although recent advances 
have revealed different pathways in cervical carcinogen-
esis, no biomarker has yet been found to be significantly 
associated with the disease recurrence or clinical outcome 
in cases of cervical cancer. Therefore, finding new serum 
tumor markers of recurrent cervical squamous cell carcino-
mas (CSCC) for evaluating the cut-off value has become a 
frequent subject of investigation in the recent years.
Nuclear protein, high mobility group box-1 (HMGB1), has 
been found to play an important role in tumor develop-
ment, growth, and spread. Increased expression of HMGB1 
has been reported in several different tumor types, includ-
ing breast carcinoma (10), colorectal cancer (11), prostate 
cancer (12), pancreatic cancer (13), and hepatocellular car-
cinoma (14). HMGB1 plays a role in metastasis develop-
ment, and thus links it to poor prognosis in a variety of 
cancers (15). In this study, we hypothesized that patients 
with recurrent cervical cancer would overexpress HMGB1 
in tissue and serum.
PatientS anD MethoDS
Patients
All patient-derived specimens were collected and archived 
under protocols approved by the institutional review 
boards of Shandong Cancer hospital and institution. Archi-
val tissues in paraffin blocks were retrieved from the De-
partment of Pathology at Shandong Cancer Hospital. Writ-
ten informed consents were obtained from the patients. 
Immunohistochemical staining of 66 recurrent CSCC par-
affin block tissues, 70 non-recurrent CSCC tissues, and 28 
healthy cervical tissues from the archive of the Depart-
ment of Pathology, was performed to analyze the cellular 
localization of HMGB1 expression.
Blood samples were obtained with the written informed 
consent from 112 women with recurrent CSCC and from 
174 women with non-recurrent carcinoma of the uter-
ine cervix at Shandong Cancer Hospital between January 
2000 and September 2008. All of the cervical cancer pa-
tients were clinically staged according to the FIGO staging 
system. Tumor size was clinically measured by magnetic 
resonance imaging scan. Plasma samples were collected 
before and after the initiation of treatment and centrifuged 
at 1500 g at 4°C for 10 minutes. The separated plasma was 
aliquoted and stored at -80°C for future analysis. Con-
trol plasma specimens (n = 128) were derived from age-
matched examinees receiving health checks at Shandong 
Cancer Hospital and showing no history of disease and no 
abnormalities in laboratory examinations. The description 
of all patients involved in this trial is presented in Table 1.
Diagnosis of local recurrence was mainly based on imaging 
examination accompanied with pelvioscopy and colpocy-








Age, year (median, range) 52 (23-77)  58 (25-82) 56 (32-79)
FiGo stage:*     
I-II 128 (73.6%) 37 (33.0%)
III-IV  46 (26.4%) 75 (67.0%)
treatment:     
surgery only  11 (6.3%)  9 (8.0%)
surgery plus adjuvant radiotherapy  30 (17.2%) 20 (17.9%)
radiotherapy alone  35 (20.1%) 26 (23.2%)
radiochemotherapy  52 (29.9%) 35 (31.3%)
radiochemotherapy plus surgery  46 (26.5%) 22 (19.6%)
*FiGo – international Federation of Gynecology and obstetrics (16).
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tology, with or without biopsy pathologic examination. Lo-
cal recurrence occurred in 96 (85.7%), liver metastases in 
7 (6.3%), lung metastasis in 4 (3.6%), and bone metastasis 
in 5 cases (4.4%). Diagnosis of pelvic recurrence was based 
on masses or parametrial invasion and nodal involvement 
found by pelvioscopy, progressively aggravated pain, and 
symptoms or signs accompanied with gradual edema of 
legs and confirmed by ultrasonography (45/96), comput-
ed tomography (32/96), and magnetic resonance imaging 
(19/96). The symptoms or signs of fibrosis caused by pelvic 
irradiation will not progressively aggravate, which can act 
as a distinction. Distant metastases were confirmed by clini-
cal examination accompanied with ultrasonography (3/16), 
computed tomography (11/16), and bone scanning (2/16).
The present study and the experiments were approved by 
the ethics committee of the Shandong Tumor Hospital and 
Institute, and all participants gave written informed con-
sent prior to participation.
enzyme-linked immunosorbent assay
Levels of HMGB1, serum squamous cell carcinoma anti-
gen (SCCA), cytokeratin fragment (CYFRA) 21-1, and car-
cinoembryonic antigen (CEA) in plasma samples were 
measured with a solid phase sandwich enzyme-linked im-
munosorbent assay (ELISA) using commercially available 
human HMGB1, CYFRA21-1, and CEA ELISA assay kits (Im-
muno-Biological Laboratories, Gunma, Japan). Plasma and 
human protein standard was diluted with EIA buffer (1% 
BSA, 0.05% Tween 20 in phosphate buffer) and incubated 
for 1 hour at 37°C. After 7 washes with EIA buffer, horse 
radish peroxidase-conjugated antibodies were added and 
incubated for 30 minutes at 4°C. After 9 washes, 100 µL of 
tetramethyl benzidine solution was added and the signal 
was allowed to develop for 30 minutes at room tempera-
ture. The reaction was stopped with 100 µL of 1 N sulfuric 
acid and the absorbance at 450 nm was measured by an 
automatic ELISA reader. Results were converted from the 
mean absorbance of duplicate wells after subtraction of 
background values. Recombinant human HMGB1, SCCA, 
CYFRA21-1, or CEA protein was used as a standard. The 
standard curve was prepared simultaneously with the 
measurement of test samples. Reagent blank, test sample 
blank, and internal controls of plasma samples were used 
to normalize values obtained from each experiment.
immunohistochemistry
Archived paraffin blocks were derived from patients who 
had surgery at Shandong Cancer Hospital. Paraffin sec-
tions were antigen-retrieved, blocked in normal horse se-
rum, and incubated in mouse anti-HMGB1 at 1:200 (Santa 
Cruz Biotechnology Inc., Santa Cruz, CA, USA) overnight 
at 4°C. After 3 washes in phosphate-buffered saline, sec-
tions were incubated with secondary antibody for 1 hour 
at 37°C. Positive reactions were detected by incubating the 
slides with stable 3,3-diaminobenzidine for 3 to 5 minutes. 
Sections were counterstained with Gill’s hematoxylin for 3 
to 6 minutes. The intensity of protein expression was evalu-
ated using OPTIMAS 6.5 software (Optimas Corp., Seattle, 
WA, USA).
Figure 1.
immunohistochemistry for high-mobility group box-1 (hMGb1) in cervical cancer clinical samples. (a)-(d) hMGb1 expression in non-recurrent cervical 
cancer; (e)-(h) hMGb1 expression in recurrent cervical cancer. original magnification: ×200. an immunostaining score was used to compare each group 
corresponding to the sum of staining intensity.
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To assess the results, we used the immunostaining score 
corresponding to the sum of staining intensity (strong pos-
itive staining in most cells – 3+; moderate staining – 2+; 
weak staining – 1+; and no evidence of staining – 0) and 
the percentage of positive cells (more than 50% of cells 
staining positive – 3+; 5-50% of cells staining positive – 2+; 
fewer than 5% of cells staining positive – 1+; and no cells 
staining positive – 0). Slides were scored in the absence of 
any clinical data, and the average score of 3 observers was 
reported as the final immunostaining score.
Statistical analysis
One-way ANOVA was used for comparison of marker se-
rum levels between the 3 groups, and a P-value lower than 
0.05 was considered significant. In addition, ROC analysis 
was performed and the area under the curve (AUC) was 
calculated separately for each of the 4 markers of interest 
and for the combinations of markers. The receiver-operat-
ing characteristic (ROC) curve, which is defined as a plot of 
testing sensitivity, as the “y” coordinate vs its 1-specificity 
or false positive rate, and as the “x” coordinate, has been 
widely accepted as the standard method for describing 
and comparing the accuracy of medical diagnostic tests 
(17,18). The overall survival and disease-free survival curves 
were calculated using the Kaplan-Meier method and the 
log-rank test. All analyses were performed using SPSS ver-
sion, 13.0 (SPSS Inc., Chicago, IL, USA).
ReSuLtS
immunohistochemistry for hMGb1 in cervical cancer 
patients
HMGB1 immunoreactivity in paraffin block sections of 66 
archival recurrent CSCCs, 70 non-recurrent CSCCs, and 
28 healthy cervical tissues was assessed by immunohis-
tochemistry. HMGB1 immunoreactivity was detected in 
47/66 (71.2%) recurrent cases and 33/70 (41.7%) non-re-
current cases. Immunohistochemical staining for HMGB1 
in representative cases of non-recurrent and recurrent 
cervical cancer (Figure 1) demonstrated that HMGB1 was 
mostly expressed in the nuclei and cytoplasm of carcino-
ma cells and some fibroblasts. HMGB1 staining was weaker 
in normal adjacent epithelial cells than in cervical cancer 
tissues.
Significantly higher mean immunostaining score was 
found in the recurrent CSCC tissue sections than in 
non-recurrent CSCC sections (2.96; 95% CI, 2.10-5.42 
vs 1.57; 95% CI, 1.10-3. 27). There was no significant differ-
ence in immunostaining scores according to age, tumor 
size, and differentiation grade (P = 0.133). However, ac-
cording to Pearson χ2 test in patients with cervical cancer, 
HMGB1 levels correlated with FIGO stage (P = 0.012), lymph 
node metastases (P = 0.028), local relapse (P = 0.008), and 
distant metastasis (P < 0.001) (Table 2).
Serum hMGb1, SCCa, CYFRa21-1, and Cea levels in 
CSCCs
Serum levels of HMGB1, SCCA, CYFRA21-1, and CEA are 
shown in Figure 2. Mean HMGB1 levels in women with re-
current CSCC (50.8 ng/mL; 95% CI, 34.4-87.l) were signifi-
cantly higher (P = 0.027) than in women with non-recur-
rent disease (15.1 ng/mL; 95% CI, 10.1-18.9) and healthy 
controls (7.6 ng/mL; 95% CI, 3.1-11.4). There was a signifi-
cant difference in serum CYFRA21-1 between patients with 
recurrent CSCC (8.4 ng/mL; 95% CI, 2.4-22.3) and patients 
with non-recurrent disease (5.1 ng/mL; 95% CI, 2.1-13.4). 
Higher serum SCCA and CEA were also observed in recur-
tabLe 2. association between the clinicopathological features 
and immunostaning score of hMGb1 in 66 recurrent CSCC and 








≤45 (n = 59) 25 (42.4) 34 (57.6)
>45 (n = 77) 31 (40.3) 46 (59.7)
FiGo stage: 0.012
I-II (n = 85) 43 (50.6) 42 (49.4)
III-IV (n = 51) 13 (25.5) 38 (74.5)
Differentiation grades: 0.146
well/ moderately 
differentiated (n = 102)
43 (42.2) 59 (57.8)
poorly differentiated 
(n = 34)
13 (38.2) 21 (61.8)
Relapse: 0.008
yes (n = 66) 19 (28.8) 47 (71.2)
no (n = 70) 37 (52.9) 33 (47.1)
Lymph node metastases: 0.028
yes (n = 71) 26 (32.4) 45 (67.6)
no (n = 65) 30 (46.2) 35 (53.8)
Distant metastasis <0.001
yes (n = 22)  4 (18.2) 18 (81.8)
no (n = 114) 52 (45.6) 62 (54.4)
*abbreviations: hMGb1 – high mobility group box chromosomal pro-
tein 1; CSCC – cervical squamous cell carcinoma; FiGo – international 
Federation of Gynecology and obstetrics (16).
†Pearson χ2 test.
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rent CSCC group, but the difference did not reach signifi-
cance (P = 0.086).
RoC curves
The serum levels of tumor markers HMGB1, SCCA, CY-
FRA21-1, and CEA were evaluated by ROC. The ROC curves 
of HMGB1 and SCCA were located closer to the theoretical 
100% sensitivity and specificity values than the ROC curves 
of other investigated markers (Figure 3). Also, the AUC of 
every tumor marker was calculated. The AUC of HMGB1, 
SCCA, CYFRA21-1, and CEA was 0.816, 0.768, 0.703, and 
0.625, respectively, suggesting clinical usefulness of the 
first 3 tumor markers for diagnosing recurrent cervical 
cancer. HMGB1 had the strongest integrative ability to dif-
ferentially diagnose cervical cancer relapse (Figure 3). The 
point closest to the upper left-hand corner of the graph 
was chosen as the cut-off point. Markers’ cut-off levels 
were as follows: HMGB1 < 21.8 ng/mL, SCCA<2.6 ng/mL, 
CYFRA21-1 < 6.2 ng/mL, and CEA<5.0 ng/mL.
We also calculated the sensitivity, specificity, positive like-
lihood ratio (PLR), and negative likelihood ratio (NLR) of 
the markers. PLR is the ratio of real positive rate to false 
positive rate, while NLR is the ratio of false negative rate to 
real negative rate. Tests with higher PLR have greater abil-
ity to confirm the disease, while tests with lower NLR have 
greater ability to exclude the disease. Our results showed 
that when comparing single tumor markers, HMGB1 had 
the best specificity and PLR (78.0% and 3.25, respectively), 
whereas SCCA had the best sensitivity and NLR (76.3% and 
0.34, respectively).
Combined measurement
A result of parallel combined testing was considered posi-
tive if the value of any of the 4 tumor markers was higher 
than the cut-off value. This test increased the diagnostic 
sensitivity to 91.48%, but decreased the specificity and PLR 
priority. In serial combined testing, a positive result was de-
fined only when the values of the 4 tumor markers were all 
higher than the cut-off value. This test decreased the diag-
nostic sensitivity, but increased the specificity and PLR to 
92.2% and 6.3, respectively (Table 3).
Sensitivity and specificity values obtained in multipara-
metric tumor marker analysis are given in Table 4. When 
2 markers were determined in identical blood sam-
Figure 2.
Serum levels of high mobility group box chromosomal protein 1 
(hMGb1) (a), squamous cell carcinoma (b), cytokeratin fragment 21-1 
(c), and carcinoembryonic antigen (d) in healthy control (n = 128), pa-
tients who remained disease free (n = 174), and patients whose disease 
relapsed (n = 112). box – 95% confidence interval of hMGb1 level; line 
– mean of 3 independent experiments; asterisk – P < 0.05 vs control.
Figure 3.
Receiver operator characteristic (RoC) curves of high-mobility group 
box-1 (hMGb1), squamous cell carcinoma antigen (SCCa antigen), cy-
tokeratin fragment 21-1 (CYFRa21-1), and carcinoembryonic antigen 
(Cea) in patients with recurrent cervical SCCa. the clinical relevance of 
hMGb1, SCCa antigen, CYFRa21-1, and Cea was compared by establish-
ing RoC curves. the RoC curves of hMGb1 and SCCa antigen were locat-
ed closer to the theoretical 100% sensitivity and specificity values than 
the RoC curves of other investigated markers.
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ples, combined sensitivity values showed that the combi-
nation of HMGB1 and SCCA (with a sensitivity of 86.65% 
in parallel combination and a specificity of 80.48% in se-
rial combination) was superior to the combinations of 
other markers. Parallel and serial combinations of 3 mark-
ers (HMGB1 in combination with SCCA and CYFRA21-1) 
lead to a superior sensitivity and specificity of 91.48% and 
87.59%, respectively. Parallel combinations of 4 markers 
did not lead to a further increase in sensitivity, however, se-
rial combination increased the specificity to 92.16%.
hMGb1 expression is correlated with prognosis in 
cervical cancer patients
HMGB1 expression in cervical cancer was significantly cor-
related with the overall survival (P = 0.018) and disease-free 
survival (P = 0.009; Figures 4A and 4B), indicating that the 
high serum level of HMGB1 was correlated with a shorter 
survival. Multivariate survival analysis, which included age, 
FIGO stage, differentiation grades, disease relapse, and 
HMGB1 expression, was carried out to determine whether 
the serum level of HMGB1 was an independent prognos-
tic factor of outcomes (Table 5). Serum HMGB1 level had 
a significant correlation with prognosis and was an inde-
pendent prognostic factor of outcomes of recurrent cervi-
cal cancer.
DiSCuSSion
We showed that HMGB1 protein was overexpressed in 
71.2% of CSCC tissues and only in 41.7% of non-recurrent 
cervical cancer tissues. HMGB1 overexpression was signifi-
cantly associated with FIGO stage, disease relapse, lymph 
node metastases, and distant metastasis. We also mea-
sured the levels of serum HMGB1 by ELISA and demon-
strated that serum HMGB1 levels were significantly higher 
in patients with recurrent cervical cancer than in patients 
with non-recurrent disease or healthy women. Compar-
ing single tumor markers, our results showed that HMGB1 
had the best specificity and PLR, whereas SCCA had the 
best sensitivity and NLR. ROC curve analysis showed that 
HMGB1 had the strongest integrative ability to differen-
tially diagnose cervical cancer relapse, stronger than SCCA, 
CYFRA21-1, or CEA. When 2 markers were determined in 
combination in identical blood samples, sensitivity values 
showed that the combination of HMGB1 and SCCA was 
superior to the combinations of other markers. HMGB1 
combined with SCCA and CYFRA21-1 lead to a superior 
sensitivity and specificity. Parallel combination of 4 mark-
tabLe 3. Sensitivity, specificity, positive likelihood ratio (PLR) 
and negative likelihood ratio (nLR) of hMGb1, SCCa, CYFRa21-
1, and Cea in parallel and serial combinations*
tumor marker Sensitivity (%) Specificity (%) PLR nLR
HMGB1 71.6 78.0 3.25 0.36
SCCA 76.3 70.6 2.60 0.34
CYFRA21-1 58.3 66.9 1.76 0.62
CEA 48.7 75.6 1.99 0.68
Parallel combination 91.5 51.8 1.90 0.16
Serial combination 49.4 92.2 6.29 0.55
*abbreviations: hMGb1 – high mobility group box chromosomal 
protein 1; SCCa – squamous cell carcinoma antigen; CYFRa21-1 – cyto-
keratin fragment 21-1; Cea – carcinoembryonic antigen.
tabLe 4. Sensitivity and specificity values of hMGb1, SCCa, CYFRa21-1, and Cea during multiparametric tumor marker analysis in 
recurrent CSCC*
Parallel combination† Serial combination‡
tumor marker sensitivity (%) specificity (%) sensitivity (%) specificity (%)
HMGB1+SCCA 86.7 68.5 64.5 80.5
HMGB1+CYFRA21-1 74.5 63.3 59.2 71.6
HMGB1+CEA 69.1 71.5 58.7 80.2
SCCA+CEA 66.7 48.7 31.0 70.4
SCCA+CYFRA21-1 61.2 41.6 40.3 62.3
CEA+CYFRA21-1 53.6 50.9 36.6 59.5
HMGB1+SCCA+CYFRA21-1 91.5 54.4 55.8 87.6
HMGB1+SCCA+CEA 88.7 60.6 54.3 82.4
HMGB1+CYFRA21-1+CEA 82.4 57.8 51.4 81.8
SCCA +CYFRA21-1+CEA 71.6 53.4 48.8 72.4
HMGB1+SCCA +CYFRA21-1+CEA 91.5 51.8 49.4 92.2
*abbreviations: hMGb1 – high mobility group box chromosomal protein 1; SCCa – squamous cell carcinoma antigen; CYFRa21-1 – cytokeratin frag-
ment 21-1; Cea – carcinoembryonic antigen.
†Parallel combined testing, a positive result was defined if the value of any of the tumor markers was higher than the cut-off value.
‡Serial combined testing, a positive result was defined only when the values of the tumor markers were all higher than the cut-off value.
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ers did not lead to a further increase in sensitivity, which 
suggested a low clinical usefulness for CEA in the diagno-
sis of CSCC.
Furthermore, we found that serum HMGB1 level was in-
versely correlated with overall survival and disease-free 
survival. The patients with higher expression of HMGB1 
had a shorter survival. In multivariate analyses, high expres-
sion of HMGB1 was a significant predictor of poor progno-
sis for recurrent CSCC patients and was an independent 
prognostic factor of outcomes of recurrent cervical cancer. 
Thus, our study showed that HMGB1, as a potentially on-
cogenic protein, might play an important role in the recur-
rence of CSCC and poor outcome. These observations pro-
vide new insight into the understanding of HMGB1 protein 
in cancer. In the present study, we did not find a significant 
difference between differentiation grades in cervical can-
cer, as we did for FIGO stage, disease relapse, and lymph 
node metastases. This may be due to the small sample size 
of poor differentiation (n = 34). However, further studies are 
needed to validate this observation.
It is well known that tumor markers play an important role 
in the diagnosis of recurrence of cancers. Cervical carcino-
ma is the most frequent disease of the reproductive organs 
and its recurrence rates are still high. Many tumor mark-
ers have been used in the diagnosis and monitoring of the 
relapse of CSCC. Serum SCCA is a commonly used serum 
marker for CSCCs. Previous studies have reported that in-
creasing serum SCCA can precede the clinical diagnosis of 
relapse in 46-92% of cases (19-21). However, it is still a mat-
ter of debate whether serum SCCA assay may represent a 
prognostic variable and be useful for earlier diagnosis of 
relapse (22,23). Most reports found CYFRA 21-1 to be a less 
sensitive serum tumor marker for squamous cell cervical 
cancer than SCCA (24-26). One-third of SCCA-negative pa-
tients are CYFRA 21-1 positive, and thus CYFRA 21-1 assay 
appears to be a useful supplementary test in a small sub-
set of patients with squamous cell cervical cancer. CEA has 
also been correlated with clinical stage, parametrial inva-
sion, tumor size, and lymph follicle metastasis in squamous 
cervical cancer (27,28).
On the other hand, measurement of these tumor markers 
has limited clinical application due to a lack of evidence on 
their specificity and accuracy. New tumor markers useful in 
the early diagnosis and in monitoring of the treatment and 
recurrence of the cervical cancer are still being sought. To 
the best of our knowledge, there has been no report about 
the relationship of HMGB1 and recurrent CSCC until now. 
In this study, we focused on the role of new tumor marker, 
HMGB1, in comparison with typical tumor markers in the 
diagnostics of cervical cancer relapse, including SCCA, CY-
FRA 21-1, and CEA.
Increased expression of HMGB1 has been reported to be 
strongly correlated with tumor genesis and tumor metas-
tasis (10-15). However, until now, there has been very little 
information about HMGB1 activity and its role in patients 
with cervical cancer. Hao et al (29) reported that the mRNA 
and protein expression of HMGB1 was significantly higher 
in CSCC than in normal cervical tissue and that it correlat-
ed with stage, invasion, and metastasis. The levels of both 
RAGE mRNA and HMGB1 mRNA were significantly higher 
in metastatic CSCC than in non-metastatic cases. We found 
significantly higher immunostaining score in the recurrent 
CSCC tissue sections than in non-recurrent disease. HMGB1 
levels correlated with FIGO stage, lymph node metastases, 
local relapse, and distant metastasis.
Tumor cells overexpressing HMGB1 might release it in 
the extracellular medium, and extracellular HMGB1 
might mediate many important functions, including 
development of a chronic inflammatory response, 
tabLe 5. Summary of survival analyses*
overall survival† Disease-free survival‡
Risk factor or classification P hazard ratio 95% Ci P hazard ratio 95% Ci
Age: ≤45 vs >45 y 0.573 1.176 0.386-1.745 0.373 0.886 0.432-1.323
FIGO stage: I-II vs III-IV 0.031 2.041 1.074-5.605 0.018 2.542 1.350-5.882
Differentiation grades: well/moderately vs poorly 0.038 1.943 0.986-4.203 0.009 2.382 1.155-5.013
Relapse: yes vs no 0.004 3.252 1.744-6.945 0.001 3.869 1.863-8.013
HMGB1 expression: <21.8 vs >21.8 ng/mL 0.021 2.124 1.089-4.526 0.007 2.928 1.454-6.325
*abbreviations: Ci – confidence interval; FiGo – international Federation of Gynecology and obstetrics (16); hMGb1 – high mobility group box 
chromosomal protein 1.
†For overall survival, the event considered was death from any cause. hazard ratios above 1.0 indicate a worse outcome.
‡For disease-free survival, the event considered was death or recurrence. hazard ratios above 1.0 indicate a worse outcome.
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promotion of tumor cell survival, expansion, and me-
tastasis through activation of intracellular signaling via 
binding to its receptor RAGE (30-33). Signaling through 
RAGE leads to the activation of the nuclear factor-kB 
pathway, mitogen activated protein kinase, type-IV col-
lagenase, and Rac/Cdc42, which are important for can-
cer cell growth, invasion, and metastasis (34-36). HMGB1 
could act as an oncoprotein because of its anti-apoptotic 
properties (10). In addition, overexpression of HMGB1 has 
been shown to cause modulation of the transcriptional 
expressing of many groups of genes reported to play 
key roles in different biological processes of neoplasm 
progression and metastasis (15). Moreover, blockade of 
HMGB1-RAGE signaling has been shown to suppress 
tumor growth and metastasis (37).
In conclusion, this study demonstrated that the level of ex-
pression of HMGB1 was highly increased in recurrent CSCC. 
HMGB1 could be a useful and specific marker for evaluat-
ing the disease recurrence and predicting prognosis in pa-
tients with CSCC. Serial combined measurements of serum 
HMGB1, SCCA, and CYFRA21-1 increased the diagnostic 
specificity, and parallel combined testing increased the di-
agnostic sensitivity. The findings in this study may provide 
an insight into the development of new approaches for ef-
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